Company profile: Cannevert Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharma research and practical applications of cannabis in therapeutics.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cannevert Therapeutics
Contineum Therapeutics
HQ: United States
Website
- Description: Provider of novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791, an LPA1R antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis (RRMS) and depression; and LPA1R DC, a peripherally restricted LPA1R antagonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Contineum Therapeutics company profile →
Aspen Neuroscience
HQ: United States
Website
- Description: Provider of personalized, autologous iPSC-derived neuron replacement therapies for Parkinson’s disease. Pipeline includes ANPD001, a personalized cell therapy for sporadic Parkinson’s disease in IND-enabling studies, and ANPD002, a gene-corrected autologous neuron therapy targeting genetic variants, focusing on the GBA gene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspen Neuroscience company profile →
Mission Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule therapeutics targeting deubiquitylating enzymes to enhance mitophagy and remove dysfunctional mitochondria for the treatment of cancer, acute kidney injury, and other diseases. Offerings include MTX325 (CNS-penetrant USP30 inhibitor), MTX652 (peripheral USP30 inhibitor), a proprietary DUB platform, and USP30 inhibitor programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mission Therapeutics company profile →
Pacira BioSciences
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products and pain management technologies, including EXPAREL, a local anesthetic used during surgery to manage pain and reduce opioid use; ZILRETTA, an extended-release injectable for osteoarthritis knee pain; ioveraº, a cryoanalgesia system delivering immediate relief; and pMVL, a multivesicular liposome drug delivery technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pacira BioSciences company profile →
Autobahn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage restorative treatments for neuropsychiatric and neuroimmunologic disorders, including ABX-002 (CNS-directed TRβ agonist for major depressive disorder), ABX-003 (next-generation TRβ-selective thyromimetic in IND-enabling studies), ABX-101 (S1P receptor modulator with neuroinflammatory and neuroprotective benefits), and a brain-targeting chemistry platform for tailored CNS/peripheral drug exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Autobahn Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cannevert Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cannevert Therapeutics
2.2 - Growth funds investing in similar companies to Cannevert Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cannevert Therapeutics
4.2 - Public trading comparable groups for Cannevert Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →